kalarx.com (KALA) - Dana dhuwit saben saham

KALA BIO, Inc. (KALA) is developing a pipeline of ophthalmological agents by implementing an innovative drug delivery system into ocular tissues. This free cash flow per share chart visualizes the current liquidity reserve, where 11.20 shows the current value of the metric. KALA BIO, Inc. (KALA) relies on inelastic demand and pricing power driven by its MSC-exosome technology. Future profits and patent protection depend on the results of the phase III trials of the secretome platform.
Rincian metrik komprehensif lan analitis KALA BIO (KALA)

For KALA BIO, Inc. (KALA), which is developing unique ophthalmological drugs amid high demand, maintaining a liquidity reserve to fund clinical trials is critically important. This calculation determines the proportion of cash within the capital structure per share, allowing investors to assess the real value of assets and avoid overpaying by analyzing the cash per share metric.